Today’s patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers.
1. 48. Introduction to the management of soft tissue sarcomas - p. 392 2. 49. Acute and chronic leukemias - p. 402 3. 50. Lymphomas - p. 411 4. 51. Multiple myeloma and cardiac amyloidosis - p. 422 5. 52. Carcinoid tumors and carcinoid heart disease - p. 432 6. 53. Neoplasms and the heart - p. 438 7. Part IV. Cancer Drugs - p. 450 8. 54. Cancer therapeutic drug guide - p. 450 9. Antitumor antibiotics and topoisomerase inhibitors including anthracyclines - p. 452 10. Alkylating agents - p. 460 11. Antimetabolites - p. 467 12. Mitosis inhibitors - p. 470 13. Monoclonal antibodies - p. 472 14. Multi-tyrosine kinase inhibitors - p. 478 15. Immune checkpoint inhibitors - p. 482 16. CAR T-cell therapy - p. 485 17. Proteasome inhibitors - p. 486 18. mTOR/phosphatidylinositol-3-kinase (PI3K) inhibitors - p. 489 19. Biological response modifiers and differentiation agents - p. 492 20. Differentiation agents and differentiation syndrome - p. 494 21. Biological response modifiers - p. 494 22. Conclusions - p. 496 23. Miscellaneous - p. 497 24. References - p. 506 25. Index - p. 507
Today’s patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers.
1. 48. Introduction to the management of soft tissue sarcomas - p. 392 2. 49. Acute and chronic leukemias - p. 402 3. 50. Lymphomas - p. 411 4. 51. Multiple myeloma and cardiac amyloidosis - p. 422 5. 52. Carcinoid tumors and carcinoid heart disease - p. 432 6. 53. Neoplasms and the heart - p. 438 7. Part IV. Cancer Drugs - p. 450 8. 54. Cancer therapeutic drug guide - p. 450 9. Antitumor antibiotics and topoisomerase inhibitors including anthracyclines - p. 452 10. Alkylating agents - p. 460 11. Antimetabolites - p. 467 12. Mitosis inhibitors - p. 470 13. Monoclonal antibodies - p. 472 14. Multi-tyrosine kinase inhibitors - p. 478 15. Immune checkpoint inhibitors - p. 482 16. CAR T-cell therapy - p. 485 17. Proteasome inhibitors - p. 486 18. mTOR/phosphatidylinositol-3-kinase (PI3K) inhibitors - p. 489 19. Biological response modifiers and differentiation agents - p. 492 20. Differentiation agents and differentiation syndrome - p. 494 21. Biological response modifiers - p. 494 22. Conclusions - p. 496 23. Miscellaneous - p. 497 24. References - p. 506 25. Index - p. 507
